Cytokines in cancer pathogenesis and cancer therapy (original) (raw)

• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour–host interface. Nature 411, 375–379 (2001).
  CAS PubMed Google Scholar
• Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27–31 (1995).
  CAS PubMed Google Scholar
• Clark, W. et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81, 1893–1904 (1989). This study was the first to demonstrate that intratumoral T-cell infiltrates are correlated with improved clinical outcomes in human melanoma.
  PubMed Google Scholar
• Clemente, C. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303–1310 (1996).
  CAS PubMed Google Scholar
• Naito, Y. et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491–3494 (1998).
  CAS PubMed Google Scholar
• Nakano, O. et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132–5136 (2001).
  CAS PubMed Google Scholar
• Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Eng. J. Med. 348, 203–213 (2003).
  CAS Google Scholar
• Dunn, G., Bruce, A., Ikeda, H., Old, L. & Schreiber, R. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991–998 (2002).
  CAS Google Scholar
• Ames, B. N., Gold, L. S. & Willett, W. C. The causes and prevention of cancer. Proc. Natl Acad. Sci. USA 92, 5258–5265 (1995).
  CAS PubMed PubMed Central Google Scholar
• Coussens, L. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
  CAS PubMed PubMed Central Google Scholar
• Ochsenbein, A. F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058–1064 (2001).
  CAS PubMed Google Scholar
• Dranoff, G. & Mulligan, R. C. Gene transfer as cancer therapy. Adv. Immunol. 58, 417–454 (1995).
  CAS PubMed Google Scholar
• Paul, W. E. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell 57, 521–524 (1989).
  CAS PubMed Google Scholar
• Janeway, C. A. Jr. How the immune system works to protect the host from infection: a personal view. Proc. Natl Acad. Sci. USA 98, 7461–7468 (2001).
  CAS PubMed PubMed Central Google Scholar
• Zinkernagel, R. M. On natural and artificial vaccinations. Annu. Rev. Immunol. 21, 515–546 (2003).
  CAS PubMed Google Scholar
• Diefenbach, A. & Raulet, D. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. 188, 9–21 (2002).
  CAS PubMed Google Scholar
• Karre, K. NK cells, MHC class I molecules and the missing self. Scan. J. Immunol. 55, 221–228 (2002).
  CAS Google Scholar
• Albert, M. et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188, 1359–1368 (1998).
  CAS PubMed PubMed Central Google Scholar
• Basu, S., Binder, R. J., Ramalingam, T. & Srivastava, P. K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14, 303–313 (2001).
  CAS PubMed Google Scholar
• Sharpe, A. H. & Freeman, G. J. The B7-CD28 superfamily. Nature Rev. Immunol. 2, 116–126 (2002).
  CAS Google Scholar
• Banchereau, J. & Steinman, R. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
  CAS PubMed Google Scholar
• Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725–729 (1996).
  CAS PubMed Google Scholar
• Old, L. & Chen, Y. -T. New paths in human cancer serology. J. Exp. Med. 187, 1163–1167 (1998).
  CAS PubMed PubMed Central Google Scholar
• Sahin, U. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA 92, 11810–11813 (1995).
  CAS PubMed PubMed Central Google Scholar
• Marincola, F. M., Jaffee, E. M., Hicklin, D. J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181–273 (2000).
  CAS PubMed Google Scholar
• Kaplan, D. et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556–7561 (1998).
  CAS PubMed PubMed Central Google Scholar
• Street, S. E., Cretney, E. & Smyth, M. J. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 97, 192–197 (2001).
  CAS PubMed Google Scholar
• Qin, Z., Kim, H. J., Hemme, J. & Blankenstein, T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon γ receptor-dependent foreign body reaction. J. Exp. Med. 195, 1479–1490 (2002).
  CAS PubMed PubMed Central Google Scholar
• Bach, E. A., Aguet, M. & Schreiber, R. D. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563–591 (1997).
  CAS PubMed Google Scholar
• Smyth, M. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661–668 (2000).
  CAS PubMed PubMed Central Google Scholar
• Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001). This study delineates an increased incidence of spontaneous carcinomas in mice deficient in Stat1 and Rag2.
  CAS PubMed Google Scholar
• Girardi, M. et al. Regulation of cutaneous malignancy by γδ T cells. Science 294, 605–609 (2001).
  CAS PubMed Google Scholar
• Girardi, M. et al. Resident skin-specific γδ T cells provide local, nonredundant regulation of cutaneous inflammation. J. Exp. Med. 195, 855–867 (2002).
  CAS PubMed PubMed Central Google Scholar
• Gao, Y. et al. γδ T cells provide an early source of interferon γ in tumor immunity. J. Exp. Med. 198, 433–442 (2003).
  CAS PubMed PubMed Central Google Scholar
• van den Broek, M. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781–1790 (1996).
  CAS PubMed Google Scholar
• Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161–169 (2002).
  CAS PubMed PubMed Central Google Scholar
• Smyth, M. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755–760 (2000).
  CAS PubMed PubMed Central Google Scholar
• Street, S. E., Trapani, J. A., MacGregor, D. & Smyth, M. J. Suppression of lymphoma and epithelial malignancies effected by interferon γ. J. Exp. Med. 196, 129–134 (2002).
  CAS PubMed PubMed Central Google Scholar
• Davidson, W., Giese, T. & Fredrickson, T. Spontaneous development of plasmacytoid tumors in mice with defective fas–fas ligand interactions. J. Exp. Med. 187, 1825–1838 (1998).
  CAS PubMed PubMed Central Google Scholar
• Siegel, R. M., Chan, F. K., Chun, H. J. & Lenardo, M. J. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nature Immunol. 1, 469–474 (2000).
  CAS Google Scholar
• Enzler, T. et al. Deficiencies of GM-CSF and interferon-γ link inflammation and cancer. J. Exp. Med. 197, 1213–1219 (2003). This study delineates a crucial role for microbial agents in the spontaneous development of lymphomas and solid tumors in Gm-csf/Ifn-γ -deficient mice.
  CAS PubMed PubMed Central Google Scholar
• Kado, S. et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor β chain and p53 double-knockout mice. Cancer Res. 61, 2395–2398 (2001).
  CAS PubMed Google Scholar
• Engle, S. J. et al. Elimination of colon cancer in germ-free transforming growth factor β1-deficient mice. Cancer Res. 62, 6362–6366 (2002).
  CAS PubMed Google Scholar
• Penn, I. Depressed immunity and the development of cancer. Cancer Detect. Prev. 18, 241–252 (1994).
  CAS PubMed Google Scholar
• Kuper, H., Adami, H. O. & Trichopoulos, D. Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171–183 (2000).
  CAS PubMed Google Scholar
• Pisani, P., Parkin, D. M., Munoz, N. & Ferlay, J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 6, 387–400 (1997).
  CAS PubMed Google Scholar
• El-Omar, E. M. et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398–402 (2000).
  CAS PubMed Google Scholar
• Nakamoto, Y., Guidotti, L. G., Kuhlen, C. V., Fowler, P. & Chisari, F. V. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188, 341–350 (1998).
  CAS PubMed PubMed Central Google Scholar
• Nakamoto, Y. et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J. Exp. Med. 196, 1105–1111 (2002).
  CAS PubMed PubMed Central Google Scholar
• Daniel, D. et al. Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med. 197, 1017–1028 (2003).
  CAS PubMed PubMed Central Google Scholar
• Fehniger, T. et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193, 219–231 (2001).
  CAS PubMed PubMed Central Google Scholar
• Hudson, J. et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375–1382 (1999).
  CAS PubMed PubMed Central Google Scholar
• Moore, R. J. et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Med. 5, 828–831 (1999).
  CAS PubMed Google Scholar
• Hilbert, D. M., Kopf, M., Mock, B. A., Kohler, G. & Rudikoff, S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med. 182, 243–248 (1995).
  CAS PubMed Google Scholar
• Lattanzio, G. et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am. J. Pathol. 151, 689–696 (1997).
  CAS PubMed PubMed Central Google Scholar
• Lin, E., Nguyen, A., Russell, R. & Pollard, J. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727–739 (2001).
  CAS PubMed PubMed Central Google Scholar
• Voronov, E. et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA 100, 2645–2650 (2003).
  CAS PubMed PubMed Central Google Scholar
• Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000). This study demonstrates that immune cells can promote tumour formation and progression.
  CAS PubMed PubMed Central Google Scholar
• Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001).
  CAS PubMed Google Scholar
• Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Eng. J. Med. 342, 1946–1952 (2000).
  CAS Google Scholar
• Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G. & Lubet, R. A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 60, 5040–5044 (2000).
  CAS PubMed Google Scholar
• Nauts, H., Fowler, G. & Bogatko, F. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med. Scand. 144, S1–S103 (1953). This report documents durable clinical remissions in response to mixed bacterial toxins.
  Google Scholar
• Interferon α versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J. Natl. Cancer Inst. 89, 1616–1620 (1997).
• Kirkwood, J. et al. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7–17 (1996).
  CAS PubMed Google Scholar
• Kirkwood, J. M. et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19, 2370–2380 (2001).
  CAS PubMed Google Scholar
• Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688–696 (1995).
  CAS PubMed Google Scholar
• Rosenberg, S. A. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85, 622–632 (1993).
  CAS PubMed Google Scholar
• Soiffer, R. J. et al. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin. Cancer Res. 2, 493–499 (1996).
  CAS PubMed Google Scholar
• Furtado, G. C., Curotto de Lafaille, M. A., Kutchukhidze, N. & Lafaille, J. J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196, 851–857 (2002).
  CAS PubMed PubMed Central Google Scholar
• Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N. & Lejeune, F. J. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 52–60 (1992).
  CAS PubMed Google Scholar
• Atkins, M. B. et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409–417 (1997).
  CAS PubMed Google Scholar
• Spitler, L. E. et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte–macrophage colony-stimulating factor. J. Clin. Oncol. 18, 1614–1621 (2000).
  CAS PubMed Google Scholar
• Rini, B. I., Weinberg, V., Bok, R. & Small, E. J. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte–macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J. Clin. Oncol. 21, 99–105 (2003).
  CAS PubMed Google Scholar
• Anderson, P. M. et al. Aerosol granulocyte macrophage–colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res. 5, 2316–2323 (1999).
  CAS PubMed Google Scholar
• Lieschke, G. J. & Burgess, A. W. Granulocyte colony-stimulating factor and granulocyte–macrophage colony-stimulating factor. N. Eng. J. Med. 327, 28–35, 99–106 (1992).
  CAS Google Scholar
• Demetri, G. D., Kris, M., Wade, J., Degos, L. & Cella, D. Quality-of-life benefit in chemotherapy patients treated with epoetin α is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. 16, 3412–3425 (1998).
  CAS PubMed Google Scholar
• Forni, G. et al. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metast. Rev. 7, 289–309 (1988).
  CAS Google Scholar
• Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993).
  CAS PubMed PubMed Central Google Scholar
• Cavallo, F. et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89, 1049–1058 (1997).
  CAS PubMed Google Scholar
• Boggio, K. et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinoma in two lines of her-2/neu transgenic mice. J. Exp. Med. 188, 589–596 (1998).
  CAS PubMed PubMed Central Google Scholar
• Mach, N. et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte–macrophage colony-stimulating factor or flt3-ligand. Cancer Res. 60, 3239–3246 (2000).
  CAS PubMed Google Scholar
• Gillessen, S. et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte–macrophage colony-stimulating factor-dependent fashion. Proc. Natl Acad. Sci. USA 100, 8874–8879 (2003).
  CAS PubMed PubMed Central Google Scholar
• Hung, K. et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357–2368 (1998).
  CAS PubMed PubMed Central Google Scholar
• Reilly, R. et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/_neu_-expressing tumors. Cancer Res. 61, 880–883 (2001).
  CAS PubMed Google Scholar
• Curcio, C. et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J. Clin. Invest. 111, 1161–1170 (2003).
  CAS PubMed PubMed Central Google Scholar
• Mach, N. & Dranoff, G. Cytokine-secreting tumor cell vaccines. Curr. Opin. Immunol. 12, 571–575 (2000).
  CAS PubMed Google Scholar
• Soiffer, R. et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte–macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 95, 13141–13146 (1998).
  CAS PubMed PubMed Central Google Scholar
• Schmollinger, J. C. et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl Acad. Sci. USA 100, 3398–3403 (2003).
  CAS PubMed PubMed Central Google Scholar
• Hodi, F. S. et al. ATP6S1 elicits potent humoral responses associated with immune mediated tumor destruction. Proc. Natl Acad. Sci. USA 99, 6919–6924 (2002).
  CAS PubMed PubMed Central Google Scholar
• Mollick, J. A., Hodi, F. S., Soiffer, R. J., Nadler, L. M. & Dranoff, G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 3, 3–20 (2003).
  PubMed Google Scholar
• Simons, J. W. et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte–macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537–1546 (1997).
  CAS PubMed PubMed Central Google Scholar
• Simons, J. et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160–5168 (1999).
  CAS PubMed Google Scholar
• Zehnter, S. et al. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology 31, 116–122 (1999).
  Google Scholar
• Shenk, T. in Fields Virology (eds Fields, B. N., Knipe, D. M. & Howley, P. M.) 2111–2148 (Lippincott–Raven Publishers, Philadelphia, 1996).
  Google Scholar
• Salgia, R. et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte–macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624–630 (2003).
  PubMed Google Scholar
• Borrello, I., Sotomayor, E., Cooke, S. & Levitsky, H. A universal granulocyte–macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum. Gene Ther. 10, 1983–1991 (1999).
  CAS PubMed Google Scholar
• Jaffee, E. et al. Novel allogeneic granulocyte–macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145–156 (2001).
  CAS PubMed Google Scholar
• Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565–594 (2001).
  CAS PubMed Google Scholar
• Doyle, A. M. et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J. Exp. Med. 194, 893–902 (2001).
  CAS PubMed PubMed Central Google Scholar
• Salomon, B. & Bluestone, J. A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225–252 (2001).
  CAS PubMed Google Scholar
• Shevach, E. M., McHugh, R. S., Piccirillo, C. A. & Thornton, A. M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol. Rev. 182, 58–67 (2001).
  CAS PubMed Google Scholar
• van Elsas, A., Hurwitz, A. & Allison, J. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355–366 (1999).
  CAS PubMed PubMed Central Google Scholar
• Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823–832 (2001).
  CAS PubMed PubMed Central Google Scholar
• Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985–988 (1995).
  CAS PubMed Google Scholar
• Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541–547 (1995).
  CAS PubMed Google Scholar
• Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003).
  CAS PubMed PubMed Central Google Scholar
• Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712–4717 (2003). This study, together with reference 107, indicates that CTLA-4 antibody blockade can be combined with cancer vaccines to increase tumour immunity in patients, albeit with a risk of compromising tolerance to self-antigens.
  CAS PubMed PubMed Central Google Scholar
• Herr, H. et al. Intravesical bacille Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 13, 1404–1408 (1995). This study demonstrates that the therapeutic administration of a mycobacteria reduces morbidity and mortality of bladder carcinoma.
  CAS PubMed Google Scholar
• Driggers, P. H., Elenbaas, B. A., An, J. B., Lee, I. J. & Ozato, K. Two upstream elements activate transcription of a major histocompatibility complex class I gene in vitro. Nuc. Acids Res. 20, 2533–2540 (1992).
  CAS Google Scholar
• Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307–317 (1996).
  CAS PubMed Google Scholar
• Hao, S. X. & Ren, R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr–Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol. Cell Biol. 20, 1149–1161 (2000).
  CAS PubMed PubMed Central Google Scholar
• Schiavoni, G. et al. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8α(+) dendritic cells. J. Exp. Med. 196, 1415–1425 (2002).
  CAS PubMed PubMed Central Google Scholar
• Schmidt, M. et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91, 22–29 (1998).
  CAS PubMed Google Scholar
• Takaoka, A. et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516–523 (2003).
  CAS PubMed Google Scholar
• Molldrem, J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Med. 6, 1018–1023 (2000).
  CAS PubMed Google Scholar
• Molldrem, J. J. et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111, 639–647 (2003).
  CAS PubMed PubMed Central Google Scholar
• Fearon, E. R. et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397–403 (1990).
  CAS PubMed Google Scholar
• Gansbacher, B. et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217–1224 (1990).
  CAS PubMed Google Scholar
• Pulaski, B. A. et al. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex re-presentation of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc. Natl Acad. Sci. USA 93, 3669–3674 (1996).
  CAS PubMed PubMed Central Google Scholar
• Tepper, R. I., Coffman, R. L. & Leder, P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257, 548–551 (1992).
  CAS PubMed Google Scholar
• Golumbek, P. T. et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713–716 (1991).
  CAS PubMed Google Scholar
• Nishimoto, N. et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95, 56–61 (2000).
  CAS PubMed Google Scholar
• Hock, H., Dorsch, M., Diamanstein, T. & Blankenstein, T. Interleukin-7 induces CD4+ T cell-dependent tumor rejection. J. Exp. Med. 174, 1291–1298 (1991).
  CAS PubMed Google Scholar
• Qin, Z., Noffz, G., Mohaupt, M. & Blankenstein, T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159, 770–776 (1997).
  CAS PubMed Google Scholar
• Brunda, M. J. et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178, 1223–1230 (1993).
  CAS PubMed Google Scholar
• Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway. Nature Immunol. 1, 515–520 (2000).
  CAS Google Scholar
• Hazama, S. et al. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo. Br. J. Cancer 80, 1420–1426 (1999).
  CAS PubMed PubMed Central Google Scholar
• Micallef, M. J., Tanimoto, T., Kohno, K., Ikeda, M. & Kurimoto, M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res. 57, 4557–4563 (1997).
  CAS PubMed Google Scholar
• Jakubowski, A. A. et al. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. Clin. Cancer Res. 2, 295–302 (1996).
  CAS PubMed Google Scholar
• Biron, C. A. Interferons α and β as immune regulators: a new look. Immunity 14, 661–664 (2001).
  CAS PubMed Google Scholar
• Tracey, K. J. & Cerami, A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45, 491–503 (1994).
  CAS PubMed Google Scholar
• Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5, 157–163 (1999).
  CAS PubMed Google Scholar
• Lynch, D. et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nature Med. 3, 625–631 (1997).
  CAS PubMed Google Scholar
• Rousseau, R. F. et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101, 1718–1726 (2003).
  CAS PubMed Google Scholar
• Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118–1122 (2001).
  CAS PubMed Google Scholar